Sempra (SRE) Proxy Filing summary

Executive summary

• Supplemental information updates the biography of director nominee Jennifer M. Kirk for the upcoming annual shareholders meeting on May 13, 2025.

• Ms. Kirk will become CEO of Exubrion Therapeutics, effective May 2025, and has joined its board.

Voting matters and shareholder proposals

• Shareholders are informed they do not need to vote again unless they wish to change or revoke their prior vote.

• Instructions for changing or revoking votes are provided in the referenced section of the proxy statement.

Board of directors and corporate governance

• Jennifer M. Kirk, standing for election to the board, has resigned from Medtronic, Inc. and will assume a CEO role at Exubrion Therapeutics.

• Ms. Kirk's updated biography is to be read in conjunction with the main proxy statement.